Efeitos neuroimunológicos do tratamento por nebulização de nanopartículas lipídicas sólidas contendo dimetil fumarato e lipossomas contendo angiotensina-1-7 em animais com encefalomielite autoimune experimental

Multiple sclerosis (MS) is a chronic, progressive, autoimmune disease characterized by inflammatory infiltrates, gliosis, demyelination, and axonal degeneration in the central nervous system (CNS). Several forms of treatment have been used to minimize the clinical symptoms of MS. However, many of th...

ver descrição completa

Detalhes bibliográficos
Autor: Bárbara Fernandes Pinto
Formato: tesis doctoral
Estado:Versión publicada
Fecha de publicación:2022
País:Brasil
Recursos:Universidade Federal de Minas Gerais (UFMG)
Repositorio:Repositório Institucional da UFMG
Idioma:portugués
OAI Identifier:oai:repositorio.ufmg.br:1843/55625
Acesso em linha:http://hdl.handle.net/1843/55625
Access Level:acceso abierto
Palavra-chave:encefalomielite autoimune experimental
dimetil fumarato
Angiotensina-1-7
nebulização
resposta inflamatória
Fisiologia
Encefalomielite autoimune experimental
Fumarato de dimetilo
Angiotensinas
Nanoestruturas
Inflamação
Descrição
Resumo:Multiple sclerosis (MS) is a chronic, progressive, autoimmune disease characterized by inflammatory infiltrates, gliosis, demyelination, and axonal degeneration in the central nervous system (CNS). Several forms of treatment have been used to minimize the clinical symptoms of MS. However, many of these drugs are expensive, have serious adverse effects and inconvenient forms of administration, reducing patient compliance. Therefore, it is important to search for new routes of administration and therapeutic strategies for the treatment of MS. The aim of this study was to evaluate the neuroimmunological effects of nebulization treatment of solid lipid nanoparticles (SLN) containing dimethyl fumarate (DMF), and of liposomes containing Angiotensin-1-7 (Ang-1-7), in mice with experimental autoimmune encephalomyelitis (EAE). The EAE model was induced in 8- to 12-week-old female C57Bl/6 mice by subcutaneous administration of emulsion containing MOG 35-55 peptide, Mycobacterium tuberculosis and Freund's complete adjuvant (CFA), followed by i.p. injection of pertussis toxin. The experimental groups received the respective treatments by nebulization for 20/21 days, every 72 hours, totalizing 7 administrations. The treatments consisted of nebulization of: a) 0.9% saline solution, b) empty SLN, c) SLN with DMF, d) empty liposomes, e) Ang-1-7, or f) liposomes with Ang-1-7. Every 72 hours, body weight and clinical score were analyzed, and at the end of treatment, data regarding CNS inflammation, pulmonary and systemic toxicity were collected. The inhaled administration of both DMF in SLN and Ang-1-7 in liposomes were effective in treating EAE animals, improving the clinical score and inflammatory response. No pulmonary toxicity associated with the use of SLNs and liposomes was evidenced. For the first time, our results show that (untreated) EAE animals showed inflammation and worsening of lung function, and that DMF in SLN and Ang-1-7 in liposomes attenuated these effects. In summary, it is suggested that nebulization of nanostructures containing DMF or Angiotensin 1-7 may be a potential therapeutic protocol for the treatment of MS, since it contributes to increase the effectiveness of the drug.